EGFR and neoplasm: To assess the efficacy of EGFR-targeted therapies in EGFR-amplified OSCC, we generated two patient tumor-derived primary cell lines (PDCLs), one harboring EGFR-amplification (TKCC-OSCC-16) and one without EGFR-amplification (TKCC-OSCC-22).